Moleculin Biotech, Inc. is a Phase 3 clinical-stage pharmaceutical company headquartered in Houston, Texas, focused on hard-to-treat tumors and viruses. Its lead candidate, Annamycin (naxtarubicin), is a next-generation anthracycline designed to avoid multidrug-resistance mechanisms and to lack the cardiotoxicity commonly associated with conventional anthracyclines. Annamycin is being evaluated in the MIRACLE trial, a pivotal, adaptive, randomized, double-blind, placebo-controlled Phase 2/3 study combining the drug with cytarabine for relapsed or refractory acute myeloid leukemia (AML). The company's broader pipeline also includes the WP1066 immune/transcription-modulator portfolio and the WP1122 glycolysis-inhibitor portfolio. Because Moleculin is pre-revenue and depends on clinical milestones and capital raises, investors follow the stock closely for trial readouts, safety data, and financing developments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, MBRX has climbed approximately 24.7%, rising from a close of $6.31 on October 21 to about $7.87 as of November 20. The advance was not a straight line: the shares touched a low near $5.30 in mid-October, spiked above $9 in late October, and have since consolidated in the $7–9 range.
The trailing quarter tells a different story. From a close of approximately $11.81 in mid-August, the stock is down roughly 33%, underscoring the volatility that has defined the name. After a sharp September drawdown and a further slide into mid-October, November's clinical and intellectual-property announcements helped stabilize the shares and drive the recent rebound.
The recent advance has been driven primarily by positive developments in the Annamycin program. On November 4, the company announced that an abstract of the first interim data from the MIRACLE trial had been accepted for the 2026 ASH Annual Meeting. The results showed complete remission rates of 43% and 36% in the two Annamycin treatment arms versus 12% in the placebo arm, with no cardiotoxicity signals reported and a recommendation from the independent Data Monitoring Committee to continue the study unchanged.
That catalyst was followed on November 16 by third-quarter financial results confirming that treatment had been completed for all 90 patients in Part A of the MIRACLE trial, keeping the program on track for a comprehensive data readout in the first quarter of 2027. Around the same period, the company announced a patent grant in Australia (November 12) and a Korean patent allowance (November 18), reinforcing the global intellectual-property estate protecting Annamycin. Collectively, these milestones improved sentiment toward the name and supported the rebound. From what I see, these updates align well with the clinical timeline investors have been tracking.
The quarterly decline reflects a difficult financing backdrop rather than a change in the clinical story. During September 2026, the company sold 888,400 common shares through an at-the-market offering for approximately $0.48 million in gross proceeds, and the exercise price of previously issued Series I warrants was reduced under anti-dilution provisions. Filings also noted that Moleculin will require significant additional financing—with no commitments in place—to complete its clinical programs. These dilution and funding concerns weighed heavily on the shares through September and October, more than offsetting the encouraging clinical data, before November's milestone announcements triggered the partial recovery.
Looking ahead, the dominant catalyst is the comprehensive Part A data readout from the MIRACLE trial, expected in the first quarter of 2027, which will inform optimal dose selection for the planned initiation of Part B in the first half of 2027. Investors are also likely to monitor the Annamycin presentation at the 2026 ASH Annual Meeting (December 12–15), any additional interim safety and efficacy updates, and further expansion of the intellectual-property portfolio. On the risk side, Moleculin's limited cash position—approximately $7.3 million as of September 30, 2026—and its stated need for additional financing remain central considerations, as any equity raise could introduce dilution. Regulatory developments, trial recruitment pace, and broader biotech risk appetite are additional factors to watch. I’m watching this closely as the data readout approaches.
In my own research process, I often turn to Tickeron’s Trending AI Robots to review curated selections of high-performing AI trading bots. The page highlights top performers and those most relevant to current market conditions, offering a range of strategies and timeframes without requiring manual sorting through the full catalog. This helps me quickly identify systematic, data-driven approaches that align with my objectives when analyzing names like MBRX.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Aroon Indicator for MBRX entered a downward trend on October 28, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 256 similar instances where the Aroon Indicator formed such a pattern. In 233 of the 256 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MBRX as a result. In 74 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MBRX's RSI Indicator exited the oversold zone, 40 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for MBRX just turned positive on November 19, 2026. Looking at past instances where MBRX's MACD turned positive, the stock continued to rise in 30 of 40 cases over the following month. The odds of a continued upward trend are 75%.
Following a +5.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBRX advanced for three days, in 176 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
MBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. MBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.306) is normal, around the industry mean (3.596). P/E Ratio (0.596) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceutical products
Industry Biotechnology